Switch theme
Sign up to access all valuation multiples
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
1887
138.1K+
LTM Revenue $89.0B
LTM EBITDA $31.5B
$403B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Johnson & Johnson has a last 12-month revenue of $89.0B and a last 12-month EBITDA of $31.5B.
In the most recent fiscal year, Johnson & Johnson achieved revenue of $88.8B and an EBITDA of $24.8B.
Johnson & Johnson expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Johnson & Johnson valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $94.9B | $85.2B | $88.8B | $89.0B | XXX |
| Gross Profit | $63.9B | $58.6B | $61.4B | XXX | XXX |
| Gross Margin | 67% | 69% | 69% | XXX | XXX |
| EBITDA | $29.0B | $23.3B | $24.8B | $31.5B | XXX |
| EBITDA Margin | 31% | 27% | 28% | 35% | XXX |
| Net Profit | $17.9B | $35.2B | $14.1B | XXX | XXX |
| Net Margin | 19% | 41% | 16% | XXX | XXX |
| Net Debt | $25.5B | $7.5B | $12.5B | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Johnson & Johnson's stock price is $162.
Johnson & Johnson has current market cap of $391B, and EV of $403B.
See Johnson & Johnson trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $403B | $391B | XXX | XXX | XXX | XXX | $10.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Johnson & Johnson has market cap of $391B and EV of $403B.
Johnson & Johnson's trades at 4.5x LTM EV/Revenue multiple, and 12.8x LTM EBITDA.
Analysts estimate Johnson & Johnson's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Johnson & Johnson and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $403B | XXX | XXX | XXX |
| EV/Revenue | 4.5x | XXX | XXX | XXX |
| EV/EBITDA | 16.3x | XXX | XXX | XXX |
| P/E | 27.8x | XXX | XXX | XXX |
| P/E/Growth | 0.7x | XXX | XXX | XXX |
| EV/FCF | 22.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpJohnson & Johnson's NTM/LTM revenue growth is 2%
Johnson & Johnson's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Johnson & Johnson's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Johnson & Johnson's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Johnson & Johnson and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 30% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.6M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 25% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 44% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Johnson & Johnson acquired XXX companies to date.
Last acquisition by Johnson & Johnson was XXXXXXXX, XXXXX XXXXX XXXXXX . Johnson & Johnson acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Johnson & Johnson founded? | Johnson & Johnson was founded in 1887. |
| Where is Johnson & Johnson headquartered? | Johnson & Johnson is headquartered in United States of America. |
| How many employees does Johnson & Johnson have? | As of today, Johnson & Johnson has 138.1K+ employees. |
| Who is the CEO of Johnson & Johnson? | Johnson & Johnson's CEO is Mr. Joaquin Duato. |
| Is Johnson & Johnson publicy listed? | Yes, Johnson & Johnson is a public company listed on NYS. |
| What is the stock symbol of Johnson & Johnson? | Johnson & Johnson trades under JNJ ticker. |
| When did Johnson & Johnson go public? | Johnson & Johnson went public in 1944. |
| Who are competitors of Johnson & Johnson? | Similar companies to Johnson & Johnson include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Johnson & Johnson? | Johnson & Johnson's current market cap is $391B |
| What is the current revenue of Johnson & Johnson? | Johnson & Johnson's last 12-month revenue is $89.0B. |
| What is the current EBITDA of Johnson & Johnson? | Johnson & Johnson's last 12-month EBITDA is $31.5B. |
| What is the current EV/Revenue multiple of Johnson & Johnson? | Current revenue multiple of Johnson & Johnson is 4.5x. |
| What is the current EV/EBITDA multiple of Johnson & Johnson? | Current EBITDA multiple of Johnson & Johnson is 12.8x. |
| What is the current revenue growth of Johnson & Johnson? | Johnson & Johnson revenue growth between 2023 and 2024 was 4%. |
| Is Johnson & Johnson profitable? | Yes, Johnson & Johnson is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
